Flerie

Flerie Invest Ab is a venture capital firm founded in 2011 and based in Stockholm, Sweden, with an additional office in London, United Kingdom. The firm specializes in early-stage and growth-stage investments, primarily focusing on companies involved in drug development and related tools or applications that address significant medical challenges. Flerie Invest aims to support innovative healthcare ventures across Europe, the United States, the United Kingdom, and Israel, contributing to advancements in the healthcare sector.

Thomas Eldered

Founder and Executive Chairman of the Board

26 past transactions

AnaCardio

Series A in 2025
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.

Vitara Biomedical

Series B in 2024
Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Microbiotica

Venture Round in 2024
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.

Synerkine Pharma

Series A in 2023
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models.

Prokarium

Series B in 2023
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

Lipum

Post in 2022
Lipum is a clinical-stage biopharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases. Its lead candidate, SOL-116, is a humanized antibody designed to target a previously overlooked molecule in the immune system, offering a novel mechanism of action that may reduce adverse effects compared to existing therapies. The primary focus of Lipum's research is on Rheumatoid Arthritis, a debilitating autoimmune disease that significantly impacts patients' quality of life. Additionally, Lipum is investigating the treatment of Juvenile Idiopathic Arthritis, which could qualify for orphan drug designation due to its rarity in children. The company is also exploring potential applications for other chronic inflammatory conditions, including Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis, addressing a significant unmet medical need in these areas.

Vitara Biomedical

Series B in 2022
Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

AnaCardio

Series A in 2022
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.

XNK Therapeutics

Venture Round in 2022
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden

Geneos Therapeutics

Series A in 2022
Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.

Strike Pharma

Venture Round in 2022
Strike Pharma specializes in personalized cancer treatment through its proprietary Adaptable Drug Affinity Conjugate (ADAC) technology. The company employs an antibody-based approach tailored to the genetic profile of each patient's tumor, effectively targeting and destroying cancer cells while sparing healthy cells. This method not only aims to enhance the efficacy of treatment but also strives to reduce the risk of side effects, making it a more affordable option for patients. By focusing on scalable personalized immunotherapy, Strike Pharma seeks to improve outcomes for individuals facing cancer.

Microbiotica

Series B in 2022
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.

Synerkine Pharma

Series A in 2021
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models.

Amarna Therapeutics

Venture Round in 2021
Based on its unique properties SVac is ideally suited for developing next generation effective gene and immune-therapies. In order to realize our ambition to become the leading global gene therapy company they formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology and gene therapy fields of research. With major regulatory, legal and intellectual property firms, they are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of the society in general.

EpiEndo Pharmaceuticals

Series A in 2021
EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.

KAHR

Venture Round in 2021
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Prokarium

Series B in 2020
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

KAHR

Series D in 2020
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Amarna Therapeutics

Venture Round in 2019
Based on its unique properties SVac is ideally suited for developing next generation effective gene and immune-therapies. In order to realize our ambition to become the leading global gene therapy company they formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology and gene therapy fields of research. With major regulatory, legal and intellectual property firms, they are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of the society in general.

Empros Pharma

Series A in 2019
Empros Pharma AB is a Swedish company founded in 2013, focused on developing pharmaceutical treatments for overweight and obesity. The company's primary product, EMP16, is an oral drug that works by delaying food digestion and absorption in the small intestine, thereby regulating food intake. Empros Pharma addresses the growing concerns related to obesity, particularly among children and adolescents, and is positioned to adapt to changes in reimbursement systems for obesity treatments. Through its innovative approach, the company aims to enhance healthcare options and improve the quality of life for individuals struggling with weight-related issues.

Prokarium

Series A in 2018
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

OxThera

Series D in 2016
OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

KAHR

Series B in 2015
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Empros Pharma

Seed Round in 2013
Empros Pharma AB is a Swedish company founded in 2013, focused on developing pharmaceutical treatments for overweight and obesity. The company's primary product, EMP16, is an oral drug that works by delaying food digestion and absorption in the small intestine, thereby regulating food intake. Empros Pharma addresses the growing concerns related to obesity, particularly among children and adolescents, and is positioned to adapt to changes in reimbursement systems for obesity treatments. Through its innovative approach, the company aims to enhance healthcare options and improve the quality of life for individuals struggling with weight-related issues.

KAHR

Series A in 2013
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Prokarium

Seed Round in 2012
Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.